DEFECTIVE OXIDATION OF DRUGS: PHARMACOKINETIC AND THERAPEUTIC IMPLICATIONSEICHELBAUM M.1982; CLIN. PHARMACOKINET.; ISSN 0312-5963; AUS; DA. 1982; VOL. 7; NO 1; PP. 1-22; BIBL. 4 P.Article

YERSINIASEN. DIFFERENTIALDIAGNOSTISCH WICHTIGE KRANKHEITEN. = YERSINIOSES. DIAGNOSTIC DIFFERENTIEL DES MALADIES IMPORTANTESEICHELBAUM M.1977; MED. WELT; DTSCH.; DA. 1977; VOL. 28; NO 40; PP. 1591-1593Article

DRUG METABOLISM IN THYROID DISEASE.EICHELBAUM M.1976; CLIN. PHARMACOKINET.; NETHERL.; DA. 1976; VOL. 1; NO 5; PP. 339-350; BIBL. 1 P. 1/2Article

DETERMINATION OF VERAPAMIL IN HUMAN BY MASS FRAGMENTOGRAPHY USING STABLE ISOTOPE-LABELLED VERAPAMIL AS INTERNAL STANDARD.SPIEGELHALDER B; EICHELBAUM M.1977; ARZNEIMITTEL-FORSCH.; DTSCH.; DA. 1977; VOL. 27; NO 1; PP. 94-97; ABS. ALLEM.; BIBL. 9 REF.Article

RAPID AND SENSITIVE METHOD FOR THE DETERMINATION OF ANTIPYRINE IN BIOLOGICAL FLUIDS BY HIGH-PRESSURE LIQUID CHROMATOGRAPHY.EICHELBAUM M; SPANNBRUCKER N.1977; J. CHROMATOGR.; NETHERL.; DA. 1977; VOL. 140; NO 3; PP. 288-292; BIBL. 19 REF.Article

DETERMINATION OF CARBAMAZEPINE AND ITS EPOXIDE METABOLITE IN PLASMA BY HIGH-SPEED LIQUID CHROMATOGRAPHY = DETERMINATION DE LA CARBAMAZEPINE ET DE SON METABOLITE EPOXYDE DANS LE PLASMA PAR CHROMATOGRAPHIE EN PHASE LIQUIDE A VITESSE ELEVEEEICHELBAUM M; BERTILSSON L.1975; J. CHROMATOGR.; NETHERL.; DA. 1975; VOL. 103; NO 1; PP. 135-140; BIBL. 24REF.Article

APPLICATION OF STABLE LABELLED DRUGS INCLINICAL PHARMACOKINETIC INVESTIGATIONSEICHELBAUM M; VON UNRUH GE; SOMOGYI A et al.1982; CLIN. PHARMACOKINET.; ISSN 0312-5963; AUS; DA. 1982; VOL. 7; NO 6; PP. 490-507; BIBL. 2 P.Article

PREDICTION OF BIOAVAILABILITY FOR DRUGS WITH A HIGH FIRST-PASS EFFECT USING ORAL CLEARANCE DATASOMOGYI A; EICHELBAUM M; GUGLER R et al.1982; EUR. J. CLIN. PHARMACOL.; ISSN 0031-6970; DEU; DA. 1982; VOL. 22; NO 1; PP. 85-90; BIBL. 26 REF.Article

INFLUENCE OF THE DEFECTIVE METABOLISM OF SPARTEINE ON ITS PHARMACOKINETICSEICHELBAUM M; SPANNBRUCKER N; DENGLER HJ et al.1979; EUROP. J. CLIN. PHARMACOL.; DEU; DA. 1979; VOL. 16; NO 3; PP. 189-194; BIBL. 9 REF.Article

EINE SPEZIFISCHE UND EMPFINFLICHE METHODE ZUR BESTIMMUNG VON PRENYLAMIN UND PRENYLAMINDERIVATEN IN BIOLOGISCHEN MATERIAL = UN PROCEDE SPECIFIQUE ET SENSIBLE POUR LA DETERMINATION DE LA PRENYLAMINE ET DES DERIVES DE LA PRENYLAMINE DANS LES PRODUITS BIOLOGIQUESEICHELBAUM M; HENGSTMANN HJ; DENGLER HJ et al.1973; ARZNEIMITTEL-FORSCH.; DTSCH.; DA. 1973; VOL. 23; NO 1; PP. 74-77; ABS. ANGL.; BIBL. 6 REF.Serial Issue

The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphismEBNER, T; EICHELBAUM, M.British journal of clinical pharmacology. 1993, Vol 35, Num 4, pp 426-430, issn 0306-5251Article

Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing: studies with deuterated verapamilEICHELBAUM, M; SOMOGYI, A.European journal of clinical pharmacology. 1984, Vol 26, Num 1, pp 47-53, issn 0031-6970Article

SUPERIORITY OF STABLE ISOTOPE TECHNIQUES IN THE ASSESSMENT OF THE BIOAVAILABILITY OF DRUGS UNDERGOING EXTENSIVE FIRST PASS ELIMINATION. STUDIES OF THE RELATIVE BIOAVAILABILITY OF VERAPAMIL TABLETSEICHELBAUM M; DENGLER HJ; SOMOGYI A et al.1981; EUR. J. CLIN. PHARMACOL.; ISSN 0031-6970; DEU; DA. 1981; VOL. 19; NO 2; PP. 127-131; BIBL. 17 REF.Article

KINETICS AND METABOLISM OF CARBAMAZEPINE DURING COMBINED ANTIEPILEPTIC DRUG THERAPYEICHELBAUM M; KOTHE KW; HOFFMANN F et al.1979; CLIN. PHARMACOL. THERAPEUT.; USA; DA. 1979; VOL. 26; NO 3; PP. 366-371; BIBL. 24 REF.Article

DISPOSITION OF VALPROIC ACID IN MAN.GUGLER R; SCHELL A; EICHELBAUM M et al.1977; EUROP. J. CLIN. PHARMACOL.; GERM.; DA. 1977; VOL. 12; NO 2; PP. 125-132; BIBL. 24 REF.Article

POLYMORPHIC OXIDATION OF SPARTEINE AND DEBRISOQUINE: RELATED PHARMACOGENETIC ENTITIESEICHELBAUM M; BERTILSSON L; SAWE DJ et al.1982; CLIN. PHARMACOL. THER.; ISSN 0009-9236; USA; DA. 1982; VOL. 31; NO 2; PP. 184-186; BIBL. 14 REF.Article

PROSPEKTIVE UNTERSUCHUNGEN ZUR EPILEPSIETHERAPIE MIT CARBAMAZEPIN = ETUDE PROSPECTIVE DU TRAITEMENT DE L'EPILEPSIE PAR LA CARBAMAZEPINEFROESCHER W; EICHELBAUM M; HILDENBRAND K et al.1982; FORTSCHRITTE DER NEUROLOGIE, PSYCHIATRIE; ISSN 0720-4299; DEU; DA. 1982; VOL. 50; NO 12; PP. 396-408; ABS. ENG; BIBL. 65 REF.Article

INFLUENCE OF MESO-CAVAL SHUNT SURGERY ON VERAPAMIL KINETICS, BIOAVAILABILITY AND RESPONSEEICHELBAUM M; ALBRECHT M; KLIEMS G et al.1980; BR. J. CLIN. PHARMACOL.; ISSN 0306-5251; GBR; DA. 1980; VOL. 10; NO 5; PP. 527-530; BIBL. 10 REF.Article

BIOAVAILABILITY OF M-OCTOPAMINE IN MAN RELATED TO ITS METABOLISM = BIODISPONIBILITE DE LA M-OCTOPAMINE CHEZ L'HOMME EN RAPPORT AVEC SON METABOLISMEHENGSTMANN JH; KONEN W; KONEN C et al.1975; EUROP. J. CLIN. PHARMACOL.; GERM.; DA. 1975; VOL. 8; NO 1; PP. 33-39; BIBL. 16REF.Article

NACHTABFALL DES CARBAMAZEPIN-SERUMSPIEGELS = CHUTE NOCTURNE DU TAUX SERIQUE DE CARBAMAZEPINEFROESCHER W; EICHELBAUM M; GUGLER R et al.1979; NERVENARZT; DEU; DA. 1979; VOL. 50; NO 3; PP. 171-178; BIBL. 38 REF.Article

THE BIOAVAILABILITY OF PHENYTOIN.GUGLER R; FROSCHER W; EICHELBAUM M et al.1977; J. NEUROL.; GERM.; DA. 1977; VOL. 216; NO 3; PP. 155-162; ABS. ALLEM.; BIBL. 27 REF.Article

PHARMACOKINETICS OF PRACTOLOL IN RENAL FAILURE = PHARMACOCINETIQUE DU PRACTOLOL DANS L'INSUFFISANCE RENALEBODEM G; GRIESER H; EICHELBAUM M et al.1974; EUROP. J. CLIN. PHARMACOL.; GERM.; DA. 1974; VOL. 7; NO 4; PP. 249-252; BIBL. 19REF.Article

Polymorphisms in the ABC drug transporter gene MDR1BRINKMANN, U; EICHELBAUM, M.Pharmacogenomics journal (Print). 2001, Vol 1, Num 1, pp 59-64, issn 1470-269XArticle

Clinical pharmacokinetics of verapamil, nifedipine and diltiazemECHIZEN, H; EICHELBAUM, M.Clinical pharmacokinetics. 1986, Vol 11, Num 6, pp 425-449, issn 0312-5963Article

USE OF STABLE LABELLED CARBAMAZEPINE TO STUDY ITS KINETICS DURING CHRONIC CARBAMAZEPINE TREATMENTEICHELBAUM M; KOETHE KW; HOFFMANN F et al.1982; EUR. J. CLIN. PHARMACOL.; ISSN 0031-6970; DEU; DA. 1982; VOL. 23; NO 3; PP. 241-244; BIBL. 15 REF.Article